Abstract
The adenosine A2A receptor is a member of the G protein-coupled receptor family and mediates multiple physiological effects of adenosine, both at the central nervous system and at peripheral tissues. Increasing evidence relates the A2A receptor with several pathological conditions such as neurodegenerative disorders, inflammation, pharmacological stress, and wound healing renewing the interest in A2A receptor agonists and antagonists as promising leads for drugs. However some of them initially tested in clinical trials presented several side effects, short half-life, lower solubility, and in some cases a lack of effects, perhaps attributable to receptor desensitization or to low receptor density in the targeted tissue. For these reasons it is evident that additional rational chemical modifications of the existing A2A receptor ligands to improve their affinity/selectivity and bioavailability as well as further studies to get new template for A2AAR ligands are necessary. The purpose of this review is to analyze and summarize the past and the present aspects related to the medicinal chemistry of A2A receptor ligands. Moreover their current and possible therapeutic applications have been also highlighted
Keywords: Adenosine, A2A receptor, A2AAR agonist, A2AAR antagonist
Current Topics in Medicinal Chemistry
Title: A2A Receptor Ligands: Past, Present and Future Trends
Volume: 10 Issue: 9
Author(s): C. Manera and G. Saccomanni
Affiliation:
Keywords: Adenosine, A2A receptor, A2AAR agonist, A2AAR antagonist
Abstract: The adenosine A2A receptor is a member of the G protein-coupled receptor family and mediates multiple physiological effects of adenosine, both at the central nervous system and at peripheral tissues. Increasing evidence relates the A2A receptor with several pathological conditions such as neurodegenerative disorders, inflammation, pharmacological stress, and wound healing renewing the interest in A2A receptor agonists and antagonists as promising leads for drugs. However some of them initially tested in clinical trials presented several side effects, short half-life, lower solubility, and in some cases a lack of effects, perhaps attributable to receptor desensitization or to low receptor density in the targeted tissue. For these reasons it is evident that additional rational chemical modifications of the existing A2A receptor ligands to improve their affinity/selectivity and bioavailability as well as further studies to get new template for A2AAR ligands are necessary. The purpose of this review is to analyze and summarize the past and the present aspects related to the medicinal chemistry of A2A receptor ligands. Moreover their current and possible therapeutic applications have been also highlighted
Export Options
About this article
Cite this article as:
Manera C. and Saccomanni G., A2A Receptor Ligands: Past, Present and Future Trends, Current Topics in Medicinal Chemistry 2010; 10 (9) . https://dx.doi.org/10.2174/156802610791268765
DOI https://dx.doi.org/10.2174/156802610791268765 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Amyotrophic Lateral Sclerosis Treatment with Ultramicronized Palmitoylethanolamide: A Case Report
CNS & Neurological Disorders - Drug Targets Insight γ-Secretase: Structure, Function, and Role in Alzheimer’s Disease
Current Drug Targets Meta-Analysis of Creatine for Neuroprotection Against Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Therapeutical Potential of CB<sub>2</sub> Receptors in Immune-Related Diseases
Current Molecular Pharmacology Glutamate and Schizophrenia: Pathophysiology and Therapeutics
Current Medicinal Chemistry - Central Nervous System Agents Targeted Drug Delivery Across the Blood Brain Barrier in Alzheimer’s Disease
Current Pharmaceutical Design Mitochondrial Permeability Transition Pore as a Suitable Targ e t for Neuroprotective Agents Against Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Frontotemporal Lobar Degeneration (FTLD): Review and Update for Clinical Neurologists
Current Alzheimer Research Prion Diseases and Emerging Prion Diseases
Current Medicinal Chemistry A Review on GABA/Glutamate Pathway for Therapeutic Intervention of ASD and ADHD
Current Medicinal Chemistry The Effect of Levosimendan on Two Distinct Rodent Models of Parkinson’s Disease
Current Alzheimer Research Quinolinyl-Thienyl Chalcones as Monoamine Oxidase Inhibitors and their In Silico Modeling Studies
Medicinal Chemistry W-F Substitutions in Apomyoglobin Increase the Local Flexibility of the N-terminal Region Causing Amyloid Aggregation: A H/D Exchange Study
Protein & Peptide Letters <i>In silico</i> Exploration of Bioactive Phytochemicals Against Neurodegenerative Diseases Via Inhibition of Cholinesterases
Current Pharmaceutical Design Current Clinical Applications of In Vivo Magnetic Resonance Spectroscopy and Spectroscopic Imaging
Current Medical Imaging Motor and Non-Motor Features of Parkinson’s Disease – A Review of Clinical and Experimental Studies
CNS & Neurological Disorders - Drug Targets Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) TNF α Signaling Beholds Thalidomide Saga: A Review of Mechanistic Role of TNF-α Signaling Under Thalidomide
Current Topics in Medicinal Chemistry Overlapping Molecular Signatures in Parkinson's Patient Leukocytes Before and After Treatment and in Mouse Model Brain Regions
CNS & Neurological Disorders - Drug Targets Half a Century of l-DOPA
Current Topics in Medicinal Chemistry